- Hyphens Pharma International (SGX:1J5)'s 1H24 results were within expectations. Revenue and PATMI were 55%/46% of our forecast. PATMI surged 52% y-o-y to S$5.3mil in 1H24. Earnings growth was driven by restocking in specialty pharma as supply chains normalise, new products and expansion of the distribution network.
- - Read this at SGinvestors.io -
- Hyphens Pharma enjoys a dividend yield of 4% and Hyphens Pharma's share price trades at a P/E ratio of 7.7x FY24e. Our BUY recommendation and DCF-based Hyphens Pharma target price of S$0.35 is maintained.
The Positive
Specialty pharma recovery post disruption.
- - Read this at SGinvestors.io -
The Negative
Investment pain at DocMed.
- Read more at SGinvestors.io.
Above is the excerpt from report by Phillip Securities Research.
Clients of Phillip Capital may be the first to access the full report in PDF @ https://www.stocksbnb.com/.
Paul Chew Phillip Securities Research | https://www.stocksbnb.com/ 2024-08-21
Previous report by Phillip:
2024-03-14 Hyphens Pharma International - More Visible Growth Drivers.
Price targets by 2 other brokers at Hyphens Pharma Target Prices.
Listing of research reports at Hyphens Pharma Analyst Reports.
Relevant links:
Hyphens Pharma Share Price History,
Hyphens Pharma Announcements,
Hyphens Pharma Dividends & Corporate Actions,
Hyphens Pharma News Articles
